Top 6 Multiple Sclerosis startups in USA
Oct 31, 2025
Like
20
1
Funding: $566.8M
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, multiple sclerosis (MS).
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, multiple sclerosis (MS).
2
Funding: $183M
Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class that advances programs in multiple sclerosis and psoriasis
Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class that advances programs in multiple sclerosis and psoriasis
3
Funding: $142.1M
Octave is a biotechnology company that uses precision medicine and scientific insights to treat patients with multiple sclerosis.
Octave is a biotechnology company that uses precision medicine and scientific insights to treat patients with multiple sclerosis.
4
Funding: $135.5M
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
5
Funding: $70M
Landos Biopharma is a developer of an oral first-in-class therapeutics designed to target autoimmune diseases.
Landos Biopharma is a developer of an oral first-in-class therapeutics designed to target autoimmune diseases.
6
Funding: $15.7M
28bio's Nerve-on-a-Chip platform facilitates prediction of both clinical neurotoxicity and efficacy in human neurodegenerative disease models earlier in the drug development pipeline.
28bio's Nerve-on-a-Chip platform facilitates prediction of both clinical neurotoxicity and efficacy in human neurodegenerative disease models earlier in the drug development pipeline.
★
See also:
